Unknown

Dataset Information

0

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.

ABSTRACT: The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy treatments, the only clinically accepted biomarker with some prediction capabilities for the outcome of the treatment is PD-L1 expression in tumor biopsies. Nevertheless, even when having PD-L1-positive tumors, numerous patients do not respond to these treatments. Considering the high cost of these therapies and the risk of immune-related adverse events during therapy, it is necessary to identify additional biomarkers that would facilitate stratifying patients in potential responders and non-responders before the start of immunotherapies. Here, we review the utility of PD-L1 expression not only in tumor cells but in immune system cells and their influence on the antitumor activity of immune cell subsets.

SUBMITTER: Bocanegra A 

PROVIDER: S-EPMC7460585 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.

Bocanegra Ana A   Blanco Ester E   Fernandez-Hinojal Gonzalo G   Arasanz Hugo H   Chocarro Luisa L   Zuazo Miren M   Morente Pilar P   Vera Ruth R   Escors David D   Kochan Grazyna G  

International journal of molecular sciences 20200818 16

The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy treatments, the only clinically accepted biomarker with some prediction capabilities for the outcome of the treatment is PD-L1 expression in tumor biopsies. Nevertheless, even when having PD-L1-positive tumors, numerous patients do not respond to thes  ...[more]

Similar Datasets

Unknown Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
| S-EPMC6159991 | biostudies-literature
Unknown Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
| S-SCDT-EMM-2019-10293 | biostudies-other
Unknown Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
| S-EPMC6609910 | biostudies-literature
Unknown Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
| S-EPMC6209395 | biostudies-literature
Unknown An update on immunotherapy with PD-1 and PD-L1 blockade.
| S-EPMC8688791 | biostudies-literature
Unknown Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
| S-EPMC6380009 | biostudies-literature
Unknown Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.
| S-EPMC5363727 | biostudies-literature
Unknown Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
| S-EPMC10085570 | biostudies-literature
Unknown Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
| S-EPMC8899589 | biostudies-literature
Unknown Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
| S-EPMC7154133 | biostudies-literature